Endo International plc / Par Pharmaceutical Holdings, Inc.

US Generic Pharmaceuticals (high-barrier generics, sterile injectables)

Disease Overview

This is a non-disease deal: Endo acquired Par to scale a US generics platform spanning oral solids, sterile injectables, and niche brands. Par's franchise concentrated on 'high-barrier' generics where complex chemistry, manufacturing difficulty, or limited competition supports above-average margins relative to commodity generics. The strategic question was whether Endo could defend those margins as commodity generic pricing eroded across 2015-2018.

Competitive Landscape

The 2015 US generics landscape was consolidating around a top tier of Teva, Mylan, Sandoz (Novartis), Actavis (which Teva would acquire for $40.5B weeks after this deal), and a chasing pack including Hikma/Roxane, Lupin, Sun, and Dr. Reddy's. Endo's prior $2.6B Qualitest buy (2010) made it a mid-tier US generics player; Par's portfolio of high-barrier generics and sterile injectables was the asset that vaulted the combined entity to the publicly stated 'top-five US generics' position by US sales. Bloomberg framed the transaction as part of an industry M&A wave driven by tax-inversion accretion math and pipeline scarcity. The deal closed September 2015 but the thesis unraveled quickly: by Q3 2016 Endo was telegraphing severe generic price erosion and impaired the Par goodwill repeatedly. The 2025 Mallinckrodt-Endo combination ultimately spun the generics business out as 'Par Health,' a tacit admission the original integration thesis underdelivered. Net: the deal that mattered for Endo's later restructuring and bankruptcy story.